1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:S45-57.
3. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081-8.
4. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
5. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001;79:515-36.
6. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008;135:821-9.
7. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012;12:408-14.
8. Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat 2013;20:745-60.
9. WHO. Global health sector strategies on viral hepatitis 2016-2021. Available from: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. [Last accessed on 28 Nov 2018].
10. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24.
11. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
13. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-3.
14. Götte M, Feld JJ. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol 2016;13:338-51.
15. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714-25.
16. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2:e319-27.
17. Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis 2018;67:1010-7.
18. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232-9.
19. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-13.
20. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015;313:1223-31.
21. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65.
22. AASLD/IDSA. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study abstract PS104. Available from: https://www.hcvguidelines.org/references/wyles-2016. [Last accessed on 28 Nov 2018].
23. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-59.
24. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685-97.
25. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404.
26. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-28.
27. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-607.
28. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493-505.
29. Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, et al. MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1-6 infection. Hepatology 2017;66:S90-1.
30. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-59.
31. Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol 2018;69:603-7.
32. Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 2016;22:446-58.
33. O’Leary JG, Fontana RJ, Brown K, Burton JR Jr, Firpi-Morell R, et al. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int 2017;30:196-208.
34. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-45.
35. Gane Ed, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, et al. EXPEDITION-4: efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1-6 infection. Hepatology 2016;64:1125A.
36. Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med 2017;166:109-17.
37. Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 2016;16:1588-95.
38. Goetsch MR, Tamhane A, Varshney M, Kapil A, Overton ET, et al. Direct-acting antivirals in kidney transplant patients: successful hepatitis C treatment and short-term reduction in urinary protein/creatinine ratios. Pathog Immun 2017;2:366-75.
39. Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371-8.
40. Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017;66:1102-10.
41. CROI. Retreatment of HCV/HIV-coinfected patients who failed 12 weeks of LDV/SOF. Available from: www.croiconference.org/sessions/retreatment-hcvhiv-coinfected-patients-who-failed-12-weeks-ldvsof. [Last accessed on 28 Nov 2018].
42. EASL. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A containing DAA regimens: results of the retreatment study. Available from: http://www.natap.org/2016/EASL/EASL_11.htm. [Last accessed on 28 Nov 2018].
43. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017;376:2134-46.
44. AASLD/IDSA. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection [Abstract 253]. Available from: https://www.hcvguidelines.org/references/zeuzem-2016. [Last accessed on 28 Nov 2018].
45. Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017;66:389-97.
46. Poordad F, Pol S, Asatryan A, Buti M, Shaw DR, et al. MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Gastroenterology 2017;152:S1057.
48. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
49. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
50. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
51. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84.
52. Johnson RJ, Gretch DR, Couser WG, Alpers CE, Wilson J, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994;46:1700-4.
53. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-44.
54. Takikawa H, Yamazaki R, Shoji S, Miyake K, Yamanaka M. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995;22:249-50.
55. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
56. Jézéquel C, Bardou-Jacquet E, Desille Y, Renard I, Lainé F, et al. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 year follow-up. J Hepatol 2015;62:S589.
57. Øvrehus ALH, Blach S, Christensen PB, Gerstoft J, Weis N, et al. Impact of prioritizing treatment in a high resource setting - minimizing the burden of HCV related disease in 15 years. J Hepatol 2015;62:S591-2.
58. CROI. Impact of deferring HCV treatment on liver-related events in HIV+ patients. Available from: http://www.croiconference.org/sessions/impact-deferring-hcv-treatment-liver-related-events-hiv-patients. [Last accessed on 28 Nov 2018].
59. Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, et al. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2016;14:15-64.
60. Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. Hepatology 2015;61:1471-8.
61. Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis 2015;212:367-77.
62. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007;46:420-31.
63. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
64. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.
65. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
66. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 2017; doi: 10.1002/hep.29408.
67. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013;207:S19-25.
68. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J 2013;10:7.
69. Wolfe D, Luhmann N, Harris M, Momenghalibaf A, Albers E, et al. Human rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy 2015;26:1072-80.
70. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57:S80-9.
71. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 2016;165:625-34.
72. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
73. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis c virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis 2016;63:1479-81.
74. Grebely J, Puoti M, Wedemeyer H, Cooper CS, Sulkowski MS, et al. Safety and efficacy of ombitasvir, paritaprevir/ritonavir and dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials. J Hepatol 2017;66:S514.
75. Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis 2016;63:1405-11.
76. Read P, Lothian R, Chronister K, Gilliver R, Kearley J, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy 2017;47:209-15.
77. Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, et al. Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy 2017;47:202-8.
78. Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, et al. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: an evaluation of programmatic and treatment outcomes. Int J Drug Policy 2017;47:187-95.
79. Norton BL, Fleming J, Bachhuber MA, Steinman M, DeLuca J, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 2017;47:196-201.
80. Boglione L, Mornese Pinna S, De Nicolò A, Cusato J, Cariti G, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study. J Viral Hepat 2017;24:850-7.
81. Grebely J, Dalgard O, Conway B, Cunningham E, Bruggmann P, et al. Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study. J Hepatol 2017;66:S513.
82. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011;54:1137-44.
83. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013;57:S39-45.
84. WHO. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Available from: http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf. [Last accessed on 28 Nov 2018].
85. AASLD/IDSA. HCV guidance: recommendations for testing, managing and treating hepatitis C. Available from: http://www.hcvguidelines.org. [Last accessed on 28 Nov 2018].
86. EASL. Recommendations on treatment of hepatitis C. Available from: http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf. [Last accessed on 28 Nov 2018].
87. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Intl J Drug Policy 2015;26:1028-38.
88. EASL. Sustained virological response to oral hepatitis C virus treatment associated with reduced mortality in an Italian cohort. Available from: https://medicalxpress.com/news/2018-04-sustained-virological-response-oral-hepatitis.html. [Last accessed on 28 Nov 2018].
89. Infohep. Direct-acting antivirals bring fewer HCV-related liver transplants, better survival after transplantation, in Europe. Available from: www.infohep.org/Direct-acting-antivirals-bring-fewer-HCV-related-liver-transplants-better-survival-after-transplantation-in-Europe/page/3257600/. [Last accessed on 28 Nov 2018].
90. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet 2016;388:1081-8.
91. Konerman MA, Lok ASF. Hepatitis c treatment and barriers to eradication. Clin Transl Gastroenterol 2016;7:e193.
92. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis 2013;57:1164-71.
93. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;368:1859-61.
94. Stein JA, Andersen RM, Robertson M, Gelberg L. Impact of hepatitis B and C infection on health services utilization in homeless adults: a test of the Gelberg-Andersen behavioral model for vulnerable populations. Health Psychol 2012;31:20-30.
95. Desai RA, Rosenheck RA, Agnello V. Prevalence of hepatitis C virus infection in a sample of homeless veterans. Soc Psychiatry Psychiatr Epidemiol 2003;38:396-401.
96. Nyamathi AM, Dixon EL, Robbins W, Smith C, Wiley D, et al. Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med 2002;17:134-43.
97. Stein JA, Nyamathi A. Correlates of hepatitis C virus infection in homeless men: a latent variable approach. Drug Alcohol Depend 2004;75:89-95.
99. Grundy G, Beeching N. Understanding social stigma in women with hepatitis C. Nurs Stand 2004;19:35-9.
100. Paterson BL, Backmund M, Hirsch G, Yim C. The depiction of stigmatization in research about hepatitis C. Int J Drug Policy 2007;18:364-73.
101. Schäfer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction 2000;95:1101-4.
102. Bogart LM, Cowgill BO, Kennedy D, Ryan G, Murphy DA, et al. HIV-related stigma among people with HIV and their families: a qualitative analysis. AIDS Behav 2008;12:244-54.
104. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. “They treated me like a leper”. Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003;18:835-44.
105. Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with hepatitis C virus: a systematic review and narrative synthesis of qualitative literature. Can J Gastroenterol Hepatol 2017;2017:3268650.
106. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-83.
107. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.
108. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008;168:1099-109.
109. Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis 2017;64:860-9.
110. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis 2013;57:S32-8.
111. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014;9:e103345.
112. Committee on a National Strategy for the Elimination of Hepatitis B and C; Board on Population Health and Public Health Practice; Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine. Eliminating the public health problem of hepatitis B and C in the United States: phase one report. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Eliminating+the+public+health+problem+of+hepatitis+B+and+C+in+the+United+States%3A+phase+one+report. [Last accessed on 28 Nov 2018].
113. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep 2015;64:453-8.
114. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014;59:1411-9.
115. Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Deﬁc Syndr 2016;73:323-31.
116. Harris AM, Iqbal K, Schillie S, Britton J, Kainer MA, et al. Increases in acute hepatitis B virus infections - Kentucky, Tennessee, and West Virginia, 2006-2013. MMWR Morb Mortal Wkly Rep 2016;65:47-50.
117. Iversen J, Grebely J, Catlett B, Cunningham P, Dore GJ, et al. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. Int J Drug Policy 2017;47:77-85.
118. Butler K, Day C, Sutherland R, van Buskirk J, Breen C, et al. Hepatitis C testing in general practice settings: a cross-sectional study of people who inject drugs in Australia. Int J Drug Policy 2017;47:102-6.
119. van Santen DK, van der Helm JJ, Lindenburg K, Schim van der Loeff M, Prins M. HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam cohort studies, 1985-2015. Int J Drug Policy 2017;47:95-101.
120. Chan DP, Sun HY, Wong HT, Lee SS, Hung CC. Sexually acquired hepatitis C virus infection: a review. Int J Infect Dis 2016;49:47-58.
121. Ingiliz P, Martin TC, Rodger A, Stellbrink HJ, Mauss S, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 2017;66:282-7.
122. Salazar-Vizcaya L, Kouyos RD, Zahnd C, Wandeler G, Battegay M, et al. Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: modeling the effect of behavioral and treatment interventions. Hepatology 2016;64:1856-69.
123. Dore GJ. Hepatitis C treatment as prevention among HIV infected men who have sex with men: feasible? Hepatology 2016;64:1834-6.
124. Martin TC, Singh GJ, McClure M, Nelson M. HCV reinfection among HIV-positive men who have sex with men: a pragmatic approach. Hepatology 2015;61:1437.
125. Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS 2015;29:2335-45.
126. Abravanel F, Métivier S, Chauveau M, Péron JM, Izopet J. Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men. Clin Infect Dis 2016;63:1271-2.
127. Pineda JA, Núñez-Torres R, Téllez F, Mancebo M, García F, et al. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. J Infect 2015;71:571-7.
128. Young J, Rossi C, Gill J, Walmsley S, Cooper C, et al. Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV. Clin Infect Dis 2017;64:1154-62.
129. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. Ann Intern Med 2016;165:625-34.
130. Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, et al. Hepatitis C reinfection after sustained virological response. J Hepatol 2016;64:1020-6.
131. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-6.
132. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83.
133. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 2013;58:1215-24.
134. UNSW. National prison entrants’ bloodborne virus and risk behaviour survey report 2004, 2007, 2010, and 2013 . Available from: https://kirby.unsw.edu.au/report/national-prison-entrants-bloodborne-virus-and-risk-behaviour-survey-report-2004-2007-2010-and. [Last accessed on 28 Nov 2018].
135. Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol 2015;7:2323-30.
136. Walmsley R. World prison population list. 11th ed. Birckbeck University of London: Institute for Criminal Policy Research; 2016.
137. United Nations. 45/111. Basic principles for the treatment of prisoners. Available from: http://www.un.org/documents/ga/res/45/a45r111.htm. [Last accessed on 28 Nov 2018].
138. Bretschneider W, Elger BS. Expert perspectives on Western European prison health services: do ageing prisoners receive equivalent care? J Bioeth Inq 2014;11:319-32.
139. de Viggiani N. Unhealthy prisons: exploring structural determinants of prison health. Sociol Health Illn 2007;29:115-35.
140. Teutsch S, Luciani F, Scheuer N, McCredie L, Hosseiny P, et al. Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health 2010;10:633.
141. Dolan K, Teutsch S, Scheuer N, Levy M, Rawlinson W, et al. Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol 2010;25:143-8.
142. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM, et al. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003;52:1500-4.
143. Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006;144:762-9.
144. Yap L, Carruthers S, Thompson S, Cheng W, Jones J, et al. A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners. PLoS One 2014;9:e87564.
145. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013;56:1078-84.
147. Spaulding AC, Perez SD, Seals RM, Hallman MA, Kavasery R, et al. Diversity of release patterns for jail detainees: implications for public health interventions. Am J Public Health 2011;101:S347-52.
149. Zickmund SL, Brown KE, Bielefeldt K. A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease? Dig Dis Sci 2007;52:2550-6.
150. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001;8:377-83.
151. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007;46:1741-9.
152. Stoové MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005;77:81-6.
153. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 2010;65:1327-9.
154. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med 2016;13:e1002032.
155. Saag MS. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. Clin Infect Dis 2015;61:169-70.
156. US Senate Committee on Finance. The Price of Sovaldi and its impact on the U.S. Health Care System. Available from: https://www.finance.senate.gov/imo/media/doc/2%20Introduction,%20Hepatitis%20C%20Background,%20Development%20of%20Sovaldi%20and%20Gilead’s%20Acquistion%20of%20Pharmasset%20(Introduction,%20Sections%201&2).pdf. [Last accessed on 28 Nov 2018].
157. WHO. Global report on access to hepatitis C treatment. Focus on overcoming barriers. Available from: http://apps.who.int/iris/handle/10665/250625. [Last accessed on 28 Nov 2018].
158. Morgan JR, Servidone M, Easterbrook P, Linas BP. Economic evaluation of HCV testing approaches in low and middle income countries. BMC Infect Dis 2017;17:697.
159. WHO. Guidelines on hepatitis B and C testing. Available from: http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/. [Last accessed on 28 Nov 2018].
160. Stein K, Dalziel K, Walker A, Jenkins B, Round A, et al. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis. J Hepatol 2003;39:814-25.
161. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012;54:1259-71.
162. Wong WW, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21.
163. Goel A, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. J Gastroenterol Hepatol 2018; doi: 10.1111/jgh.14301.
164. Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing: innovations in testing technologies and approaches. BMC Infect Dis 2017;17:699.
165. Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat 2014;21:1-4.
166. Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014;21:5-33.
167. Chen DS, Hamoudi W, Mustapha B, Layden J, Nersesov A, et al. Strategies to manage hepatitis C virus infection disease burden-Volume 4. J Viral Hepat 2017;24:44-63.
168. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, et al. Chronic hepatitis C virus infection in the United States, National health and nutrition examination survey 2003 to 2010. Ann Intern Med 2014;160:293-300.
169. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, et al. The present and future disease burden of hepatitis c virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;21:34-59.
170. Hepatitis B and C Public Policy Association ASBL. Hepatitis C elimination in Europe - European policy guidelines. Available from: http://www.hcvbrusselssummit.eu/images/documents/reports/HCV-Elimination-PolicyGuidelines.pdf. [Last accessed on 28 Nov 2018].
171. Arora S, Thornton K, Murata G, Deming P, Kalishman S, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011;364:2199-207.
172. Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol 2008;22:27-32.
173. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013;56:1078-84.
174. Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol 2008;22:27-32.
175. Nazareth S, Kontorinis N, Muwanwella N, Hamilton A, Leembruggen N, et al. Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth. J Telemed Telecare 2013;19:101-6.
176. Beste LA, Glorioso TJ, Ho PM, Au DH, Kirsh SR, et al. Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the department of veterans affairs. Am J Med 2017;130:432-8.
177. Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med 2017;167:311-8.
178. Mera J, Vellozzi C, Hariri S, Carabin H, Drevets DA, et al. Identification and clinical management of persons with chronic hepatitis C virus infection - Cherokee Nation, 2012-2015. MMWR Morb Mortal Wkly Rep 2016;65:461-6.
179. Hellard M, Sacks-Davis R, Doyle J. Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks. J Epidemiol Community Health 2016;70:1151-4.
180. Centers for Disease Control and Prevention (CDC). Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6105a1.htm. [Last accessed on 28 Nov 2018].
181. Scott N, Ólafsson S, GottfreÐsson M, Tyrfingsson T, Rúnarsdóttir V, et al. Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020. J Hepatol 2018;68:932-9.
182. European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325-36.
183. Dore GJ, Hajarizadeh B. Elimination of hepatitis C virus in Australia: laying the foundation. Infect Dis Clin North Am 2018;32:269-79.
184. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and C. Modeling the Elimination of Hepatitis C in the United States. In: Strom BL, Buckley GJ, editors. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. Washington (DC): National Academies Press (US); 2017.
185. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014;59:1411-9.
186. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;368:1859-61.
187. Belperio PS, Chartier M, Gonzalez RI, Park AM, Ross DB, et al. Hepatitis C care in the department of veterans affairs: building a foundation for success. Infect Dis Clin North Am 2018;32:281-92.
188. HHS.gov. The community response to viral hepatitis - contributions towards achieving the goals of the viral hepatitis action plan. Available from: https://www.hhs.gov/hepatitis/action-plan/viral-hepatitis-community-action/community-response-to-viral-hepatitis/index.html. [Last accessed on 29 Nov 2018].
189. Waked I, Doss W, El-Sayed MH, Estes C, Razavi H, et al. The current and future disease burden of chronic Hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014;15:45-52.
190. The World Bank. Treatment program policy analysis 2017 (English). Available from: http://documents.worldbank.org/curated/en/335981517329520478/Treatment-program-policy-analysis-2017. [Last accessed on 28 Nov 2018].
191. The World Bank. Eliminating hepatitis C from Egypt: 2017 update on current trends and policyrecommendations - policy brief (English). Available from: http://documents.worldbank.org/curated/en/164381517333701631/Eliminating-Hepatitis-C-from-Egypt-2017-update-on-current-trends-and-policyrecommendations-policy-brief. [Last accessed on 28 Nov 2018].
192. Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, et al. Launch of a nationwide hepatitis C elimination program - Georgia, April 2015. MMWR Morb Mortal Wkly Rep 2015;64:753-7.
193. Gvinjilia L, Nasrullah M, Sergeenko D, Tsertsvadze T, Kamkamidze G, et al. National progress toward hepatitis C elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep 2016;65:1132-5.
194. Nasrullah M, Sergeenko D, Gvinjilia L, Gamkrelidze A, Tsertsvadze T, et al. The role of screening and treatment in national progress toward hepatitis C elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep 2017;66:773-6.
195. WHO. Brazil sets out path to eliminate hepatitis C by 2030. Available from: http://www.worldhepatitissummit.org/docs/default-source/press-releases/government-of-brazil/brazil-sets-out-path-to-eliminate-hepatitis-c-by-2030.pdf?sfvrsn=2. [Last accessed on 28 Nov 2018].
196. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015;61:1860-9.
197. Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, et al. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat 2016;23:631-43.
198. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 2016;65:17-25.
199. Hickman M, Martin NK, Huxtable R. Hepatitis C virus prevention and treatment prioritization - ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. Addiction 2017;112:201-3.
200. Lazarus JV, Stumo SR, Harris M, Hendrickx G, Hetherington KL, et al. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. J Int AIDS Soc 2018;21:e25052.
203. Sixty-seventh World Health Assembly. Hepatitis. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf. [Last accessed on 28 Nov 2018].
204. Lazarus JV, Mozalevskis A, Safreed-Harmon K, Eramova I. Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014). Hepatol Med Policy 2016;1:3.
205. WHO. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Available from: www.measlesrubellainitiative.org/wp-content/uploads/2013/06/WHO-surveillance-standard.pdf. [Last accessed on 28 Nov 2018].
206. Irving WL, Brown RJ. Acute hepatitis C virus infection: a dynamic-and challenging-concept. J Infect Dis 2010;202:1765-7.
207. Klevens RM, Miller J, Vonderwahl C, Speers S, Alelis K, et al. Population-based surveillance for hepatitis C virus, United States, 2006-2007. Emerg Infect Dis 2009;15:1499-502.
208. The National Academies Press. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C (2010). Available from: http://www.nap.edu/catalog/12793.html. [Last accessed on 28 Nov 2018].